Page 143 - Read Online

Page 395 Santiago et al. J Transl Genet Genom 2021;5:380-95 https://dx.doi.org/10.20517/jtgg.2021.16

NTRK3 rearrangement. Blood Adv 2020;4:106-11. DOI PubMed PMC
91. Tran TH, Nguyen JV, Stecula A, et al. The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and
detectable in clinical samples prior to treatment. Haematologica 2021. DOI PubMed
92. Churchman ML, Low J, Qu C, et al. Efficacy of retinoids in IKZF1-mutated BCR-ABL1 acute lymphoblastic leukemia. Cancer Cell
2015;28:343-56. DOI PubMed PMC
+
93. Churchman ML, Evans K, Richmond J, et al. Synergism of FAK and tyrosine kinase inhibition in Ph B-ALL. JCI Insight
2016;1:86082. DOI PubMed PMC
94. Diaz-Flores E, Comeaux EQ, Kim KL, et al. Bcl-2 is a therapeutic target for hypodiploid B-lineage acute lymphoblastic leukemia.
Cancer Res 2019;79:2339-51. DOI PubMed PMC
95. Griffith M, Griffith OL, Krysiak K, et al. Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a
patient with relapsed adult B-lymphoblastic leukemia. Exp Hematol 2016;44:603-13. DOI PubMed PMC
96. Habets RA, de Bock CE, Serneels L, et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH
inhibition. Sci Transl Med 2019;11:eaau6246. DOI PubMed
97. Yuan T, Yang Y, Chen J, et al. Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b
mechanism reveals a critical targetable role for PIK3CD. Leukemia 2017;31:2355-64. DOI PubMed PMC
98. Alonso-Alonso R, Mondéjar R, Martínez N, et al. Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic
leukemia and T-cell lymphoma. Sci Rep 2020;10:6721. DOI PubMed PMC
99. Khaw SL, Suryani S, Evans K, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged
leukemia. Blood 2016;128:1382-95. DOI PubMed PMC
100. Gaussmann A, Wenger T, Eberle I, et al. Combined effects of the two reciprocal t(4;11) fusion proteins MLL.AF4 and AF4.MLL
confer resistance to apoptosis, cell cycling capacity and growth transformation. Oncogene 2007;26:3352-63. DOI PubMed
101. Inukai T, Zhang X, Goto M, et al. Resistance of infant leukemia with MLL rearrangement to tumor necrosis factor-related apoptosis-
inducing ligand: a possible mechanism for poor sensitivity to antitumor immunity. Leukemia 2006;20:2119-29. DOI PubMed
102. Peirs S, Matthijssens F, Goossens S, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute
lymphoblastic leukemia. Blood 2014;124:3738-47. DOI PubMed
103. Fischer U, Forster M, Rinaldi A, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia
identifies recurrent mutation patterns and therapeutic options. Nat Genet 2015;47:1020-9. DOI PubMed PMC
104. Farhadfar N, Li Y, May WS, Adams CB. Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia: a
case report and review of literature. Hematol Oncol Stem Cell Ther 2021;14:246-51. DOI PubMed
105. La Starza R, Cambò B, Pierini A, et al. Venetoclax and bortezomib in relapsed/refractory early T-cell precursor acute lymphoblastic
leukemia. JCO Precis Oncol 2019;3:PO. DOI PubMed PMC
106. Karol SE, Cooper TM, Bittencourt H, et al. Safety, efficacy, and PK of the BCL2 inhibitor venetoclax in combination with
chemotherapy in pediatric and young adult patients with relapsed/refractory acute myeloid leukemia and acute lymphoblastic
leukemia: Phase 1 Study. Blood 2019;134:2649. DOI
107. Lacayo NJ, Pullarkat VA, Stock W, et al. Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric
relapsed/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 2019;134:285. DOI
108. Kluk MJ, Lindsley RC, Aster JC, et al. Validation and implementation of a custom next-generation sequencing clinical assay for
hematologic malignancies. J Mol Diagn 2016;18:507-15. DOI PubMed PMC
109. Harvey RC, Tasian SK. Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic
leukemia. Blood Adv 2020;4:218-28. DOI PubMed PMC
110. Schieck M, Lentes J, Thomay K, et al. Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-
BFM ALL 2017 trial on acute lymphoblastic leukemia. Ann Hematol 2020;99:809-18. DOI PubMed PMC
111. Inaba H, Azzato EM, Mullighan CG. Integration of next-generation sequencing to treat acute lymphoblastic leukemia with targetable
lesions: the St. Jude Children's Research Hospital Approach. Front Pediatr 2017;5:258. DOI PubMed PMC